Sextant Therapeutics
Cambridge
About Sextant Therapeutics
Sextant develops groundbreaking cancer therapies from our patented drug discovery technologies developed at MIT. Instead of simply trying to kill the tumor, we have created a way for tumors to dynamically trigger an immune response against cancer, and our technologies help us discover the best drug combinations to prevent relapse. Sextant’s unique pre-clinical drug discovery platform could bring new, more effective chemotherapies to market and save millions of lives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Last round: Grant (Nov 2012)
- Website: sextantbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/sextant-therapeutics-740935 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.